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ABSTRACT
Objective: To analyze the results of hysteroscopic
myomectomy in our center and to compare the results to
those published in the literature.
Methods:  We performed a retrospective study of the
clinical histories of patients who had undergone hystero-
scopic myomectomy with a resectoscope between
January 1992 and December 1999. Procedures were per-
formed at a hysteroscopic clinic in the Department of
Obstetrics and Gynecology at the University Public
Hospital in Madrid’s south zone. One hundred twenty
pre-, peri-, and postmenopausal women with submucous
myomas were included in the study. All patients under-
went hysteroscopic resection with a monopolar loop.
Results: We performed 120 hysteroscopic myomec-
tomies. The patients’ median age was 44.8 years (23 to
74). Abnormal uterine bleeding (AUB) was the most fre-
quent indication (84.1%). Inability to reproduce was the
indication in 14 (11.6%) cases. GnRH analogue prepara-
tion was used in 60% of cases. We operated on 52
(43.3%) type 0, 51 (42.5%) type I, and 17 (14.1 %) type
II myomas, according to Wamsteker and Blok classifica-
tion.1 A median of 32.5 (10 to 105) minutes was required
for the interventions. The myomectomy was combined
with another operation (12 polypectomies, 24 endome-
trial resections, and 1 laparoscopic ovarian cystectomy)
in 32 patients. The median retention of glycemia was 281
cc (0 to 1300). We could not complete the resection in 22
patients. Twelve underwent reoperation (3 hysterec-
tomies and 9 second myomectomies). No serious com-
plications occurred, and the median hospital stay was
25.4 hours. The histological study confirmed leiomyoma
in all the cases. The intervention results were satisfacto-
ry after a follow-up period of 12 months to 7 years, AUB
being controlled in 88.5% of the patients.
INTRODUCTION
The most frequent solid tumor in the feminine pelvis is
the uterine myoma. It appears in 20% to 40% of women
older than 30 years, causing 3% to 5% of gynecology
consultations;2 and today it is the main cause for hys-
terectomy (67% of the indications in the USA).3
A high frequency of symptoms, such as bleeding, pain,
or reproductive problems, is caused by submucous
myomas (5% to 10 %). Until the introduction of the hys-
teroscopic technique, therapeutic and diagnostic man-
agement was limited. Hysterectomy frequently was pre-
sented as the only possible solution for these patients,
particularly if the desire to procreate had been satisfied.
A conservative solution to the problem in young patients
was more complicated.
Because of endoscopic technical advances, we can now
offer the patient a better diagnosis and less expensive
treatment with the same efficacy as treatments that are
more aggressive.
The technique is a valid alternative to classical methods
(hysterectomy or myomectomy). Many series of patients
as well as diverse methods (cold scissors, monopolar
resectoscope, laser, versaponit) have been reported on
since 1976 when Neuwirth performed the first hystero-
scopic myomectomy.4 We present our series and the
results obtained with this technique in connection with
those published by other authors.5-13
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Conclusion: Hysteroscopic myomectomy is a reliable
procedure that is effective in controlling abnormal uter-
ine bleeding. It is a good alternative to hysterectomy and
has an acceptable surgical time and minimum hospital
stay. To reduce the need of reintervention, appropriate
patient selection and improved technique are necessary.
The technique also offers significant economic savings
compared with the conventional surgical methods.
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MATERIALS AND METHODS
We performed 120 hysteroscopic myomectomies from
January 1992 to December 1999. The patients were
referred to our clinic from Madrid’s XI zone, the hospital’s
external clinics, and clinics from other provinces.
Abnormal uterine bleeding (AUB) was the main reason
patients came to the clinic; only 14 patients came because
of sterility/infertility. In every case, a basic gynecologic
exploration, anamnesis, smear, vaginal fortis, vaginal
scan, and optional hysterosonography were carried out.
The diagnostic hysteroscopy was good for making a pre-
cise diagnosis, for clarifying the myoma type, size, num-
ber, and location as well as to determine the possibilities
or not for a hysteroscopic resection. We carried out, 6 to
8 weeks after the surgery, optional hysteroscopic second
looks as a control. We used the Wamsteker and Blok clas-
sification.
Patient selection criteria are listed in Table 1. Once deter-
mined suitable for the operation, the patients underwent
standard preoperative examination. We treated pre-
menopausal women and women with a 2-cm or larger
myoma with Danazol or GnRH analogues. The operation
was performed 3 to 5 weeks after the final doses. The
patients were then admitted to the “day hospital,” which
was created in 1997.
In every case, we used a 9-mm double-way resectoscope,
27050E Karl Storz model, with a 4-mm, 12° or 30°
Hopkins optic. Glycine solution (1.5%) was the mecha-
nism used to distend the cavity. We introduced it into the
cavity with a 26331020 Karl Storz Hamou Endomat bomb,
using 250 to 300 mL/min flow, 80 to 100 mm Hg perfu-
sion pressure, and 10 to 20 mm Hg aspiration pressure.
We used a monopolar scalpel with an 8-mm and 90° ter-
minal loop of 60 to 100 W of intensity for cutting and 50
W for clotting. We began the intervention with low cut-
ting energy. Later, we adjusted it in accordance with the
tissue consistency.
We induced cervical dilation with the sign of Hegar until
the number 10. Under direct vision, we introduced the
resectoscope; next, we explored the entire cavity reeval-
uating the myoma, mainly,  gonadotropin-releasing hor-
mone (GnRH) analogue preparation was used. To avoid
bleeding during the intervention, we began by coagulat-
ing the superficial margin vases. Next, in a methodical
and progressive manner, we removed the myoma. We
removed the chips when they did not allow appropriate
visualization. Determination of the liquid balance was
carried out every 15 to 20 minutes. The intervention was
complete when the entire myoma was removed or the
glycine balance was greater than 1000 to 1500 cc.
Ultrasonic or laparoscopic intraoperation control was not
used systematically. Prophylactic antibiotics or vasocon-
stricting agents were not used. Estrogen-progestogen
treatment was used when the affected endometrial sur-
face was broad to avoid postsurgical adhesions. When
the operation was over the patient was taken to the hos-
pital.
RESULTS
The patients’ median age was 44.8 years (23 to 74).
Eighteen were postmenopausal women. The biggest
group was that between 40 and 50 years of age (40%).
The median parity was 1.6 deliveries (0 to 6), 25.8 %
being nulliparous.
AUB was the reason for a consult in 84.1% of cases and
infertility-sterility problems were the reason in 11.6 %.
We emphasize that in 48.9% of our patients, endometrial
pathology was suspected because of ultrasound findings.
GnRH analogue preparation was used in 72 patients (60
%), Danazol in 9 (7.5%), and no preparation in 39
(32.5%).
Table 2 provides information regarding patients’ age,
indication, type and size of myoma, and the preoperative
therapy used. A single procedure was performed in 83
(69.2%) patients and associated procedures (12 polypec-
tomies, 24 endometrial resections, 1 laparoscopy because
of a benign adnexal tumor) were performed in 37
(30.8%). The global median of retained glycine was 281
cc (0 to 1300); 270 cc (0 to 1300) for single procedures
Table 1.
Patient Selection Criteria
1. Existence of an indication
2. The patient wants to preserve her uterus
3. Myoma size < 6 cm
4. Endometrial surface affected < 50% 
5. Contraindicated in myoma type V of Labastida’s Classification24
6. Absence of associated pathology that contraindicated the 
procedureand 302 cc (0 to 1000) for combined ones. Significant sta-
tistical differences were found for myomas smaller than
3 cc and for those larger or similar (192/305 cc) (P <
0.05). A significant statistical difference was also found
among glycine balances for myomas type 0, I, and II.
Table 3 provides information on surgical time, glycine
balance, and duration of hospital stay.
Regional anesthetic was used in 49.1% of interventions,
general in 14.1%, general with laryngeal mask in 25%,
and local plus sedation in 11.6%. The absence of serious
complications is noteworthy. One uterine perforation
occurred. It was resolved by laparoscopy, discarding the
hollow visceral lesion and establishing homeostasis. A
cervical laceration occurred in a patient who received
previous GnRH analogue treatment, which required 2
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sutures. A false road with no perforation, a hemorrhage
that resolved with an intrauterine Foley, and an infection
resolved with antibiotic therapy occurred. Also, sickness,
nausea, and time-space transitory disorientation occurred
in a patient with a glycine balance of about 1000. In this
case, intrathecal morphine was used, the lowest sodium
value being 32 mEq/L.
The myomectomy was not complete in 22 cases. Myoma
type, size, number, and surgical time and glycine balance
are presented in Table 4. The follow-up of 107 patients
(89.1 % of the sample) was done with a median time of
2.8 years (6 months to 7 years). Twelve reinterventions
[3 hysterectomies (2.8%) and 9 myomectomies (8.4 %)]
were performed during this time. In all the cases, the first
myomectomy was incomplete (Table 4).
The median stay (Table 3) of our patients was 25.4 hours
(12 to 144). A nonsignificant percentage of our patients
were not admitted to the minimum stay unit because
they were operated on before its creation, because they
were living far from Madrid, or because of medical prob-
lems unsuspected at the time of the intervention. Flat
muscular fibers were demonstrated in all the cases on the
histological study. In 3 cases, a mixed adenomyoma
component was found. No formless histological malig-
nancy was found.
DISCUSSION
The most common symptom that motivates patients to
seek medical attention is AUB. This results in diagnosis
and surgical treatment of uterine myomas in general and
submucous myomas in particular. In every publication
reviewed, the most common indication reported for
intervention was AUB. In 1995, Hallez7 reported a series
of 274 hysteroscopic myomectomies in which the indica-
tion was AUB. Recently, Vercellini9 reported that some
type of AUB was present in two thirds of his 121 patients.
Lure and colleagues14 refer to this symptom in 74.8% of
their patients. In our patients, 84.1% presented with this
symptom. We can find it in pre- and postmenopausal
women, mainly in connection with hormone replace-
ment therapy.
Reproductive problems are the second leading indication
for hysteroscopic myomectomy. In Hallez’s series7 refer-
ered to above, only 32 (13.9%) of 229 premenopausal
patients had this problem. Cayuela15 reports a series of
104 patients, 5% of whom were sterile-infertile patients.
Table 2.
Age, Indication, Type/ Size Myoma, Preoperative Therapy*
n%
Age(23-74 yrs)
<30 7 5.8
30-40 27 22.5
40-50 48 40.0
50-60 30 25.0
60-70 6 5.0
>70 2 1.6
Indication
AUB† 101 84.1
Est/Infer 14 11.6
Pain 7 5.8
Birth/Myoma 5 4.1
Type‡
0 52 43.3
I 51 42.5
II 17 14.1
Size
1 5 4.1
2 31 25.8
3 63 52.5
4 19 15.9
5 2 1.7
Preoperative therapy
No therapy 39 32.5
Danazol 9 7.5
GnRH analog 72 60.0
*N: 120.
†AUB: Abnormal uterine bleeding.
‡Type of myoma according to Wamsteker and Blok classification.1Hysteroscopic Myomectomy: Our Experience and Review, Muñoz JL et al.
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Vercellini,9 however, reports 32% of patients with repro-
ductive problems. In our series, only 14 (11.6%) were
operated on for this reason.
Diagnostic imaging techniques, particularly ultrasound,
for diagnosing intrauterine pathology are a great help. In
many cases, the ultrasound leads us to suspect intrauter-
ine pathology in asymptomatic patients. In these cases,
to ensure the diagnosis, directed biopsies should be
taken, the treatment outlined, and the diagnostic hys-
teroscopy forced. For asymptomatic patients, we do not
think the hysteroscopic myomectomy is suitable; but to
ensure the diagnosis, a directed hysteroscopic biopsy is
indispensable and  a scan and hysteroscopic controls are
done optionally. If clinical symptoms appear or the
myoma grows, surgery must be quickly reconsidered. In
this case, we agree with the general opinion of authors
in the literature review.14-18
Less frequently, dysmenorrhea or nonspecific pelvic pain
may justify hysteroscopic myomectomy if no other rea-
son explaining the symptoms is found. In 1995, Hallez7
reported secondary dysmenorrhea in 48 (20.9%) of 229
premenopausal women, although, in how many of these
cases the pain was associated with another symptom
such as AUB is not specified. We found only abdominal
pain as the indication for surgery in 6 patients and in half
of these bleeding was associated.
Not all diagnosed submucous myomas result from sur-
gery, and the hysteroscopic method cannot always be
used.
Common sense must be used in selecting patients. It is
logical to consider in the first place an option that offers
less risk, a minor hospital stay, lower costs, avoids scar-
ing and intraabdominal adhesions, and controls the
Table 3.
Surgical Time, Glycine Balance, Duration of Hospitalization
Surgical Time (min) Glycine Balance (mL) Hospitalization
Simple Procedures* Simple Procedures‡ Combined Procedures|| Hours n %
<3 cm 26.5(10-45) <3 cm 192 <3 cm 317 12 15 47.5
>3 cm† 36.3(10-105) >3 cm 305§ >3 cm 355¶ 24 33 27.5
Type 0 206§ Type 0 323¶ 36 5 4.3
Type I 337§ Type I 347† 48 17 14.1
Type II 500§ Type II 600† 72 7 5.8
>72 1 0.8
*Combined median: 32.5 min, combined range: 10-105 min.
†P<0.01.
‡Combined median: 270 mL.
§P<0.05.
||Combined median: 302 mL.
¶P: NS.
Table 4.
Incomplete Myoma Resection*
n%
Type
0 6 27.2
I 10 45.4
II 6 27.2
Size
<3 cm 5 22.7
>3 cm 17 77.3
Number
Single 16 72.7
Multiple 6 27.3
Reinterventions
Hysterectomies 3 2.8
Myomectomies 9 8.4
*Surgical time (min): mean–40, range–20-75, median for simple
procedures–32.5; Glycine balance (mL): mean–581, range–350-
1300, median total glycine balance–281.patients’ symptoms. The patient’s wish to conserve the
uterus will be a fundamental consideration condition
whether desires to procreate are fulfilled or not.
Some limits are outlined by the authors in connection
with myoma size and number. Neuwirth19 and Blanc20
limit treatment to myomas not bigger than 4 to 5 cm.
However, other authors approve up to 6 cm.7 On the
other hand, hysteroscopic myomectomy would not be
advisable if more than 50% of the endometrial surface is
affected by the myoma size or number.
The size of the uterine cavity has been limited to that at
16 weeks of pregnancy or to 10, 12, or 15 cm.21-23
Hysteroscopic myomectomy is not advised if the uterus
is greater than these sizes. We believe that all these cri-
teria must be individually evaluated, keeping in mind
each patient’s peculiar condition as well as the surgeon’s
own experience and ability. In certain cases, hys-
teroscopy may be possible if uterine size is close to the
maximum, but resecting large myomas should be care-
fully considered because risk increases as the number
and size of the myomas increase.17
Labastida type V submucous myomas are disregarded.24
We think the intramural myoma component is a funda-
mental limiting factor to hysteroscopic resection.
Hysteroscopic boarding is possible in the rest of the
cases. Hallez18 described a maneuver favoring the expul-
sion of the intramural component in the cavity when a
submucous myoma is removed. Such maneuvers can be
useful in some Wamsteker type II myomas. If, in spite of
these maneuvers, part of the myoma remains, we must
suspect that the myoma is bigger than previously calcu-
lated (Labastida type V) and perhaps we must finish the
intervention without complete myoma resection.
Other associated severe pathologies,21 heart or hepatic,
as well as other gynecologic diseases cause us to recon-
sider the use of the hysteroscopic method for treating
submucous myomas. Previous interventions used various
types of medication (Progestogens, Danazol, GnRH ana-
logues) to improve surgical conditions, to diminish risk,
and to improve the results. The most used and generally
accepted are the GnRH analogues.3,25-31 Certainly, they
offer some advantages in reducing size and improving
vascularization of myomas and reducing the thickness
and vascularization of the endometrium, improving
blood levels. However, these medications have adverse
effects, which include hot flashes, spotting, cervical dila-
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tion problems, lacerations, and even perforations. All
these may occur in addition to the uterine cavity volume
reduction that will make mobility and handling of the
resectoscope difficult. Because of these, some authors do
not find advantages in their use. Romer32 did not find dif-
ferences in the surgical times, glycine balance, blood
loss, or postoperation development with analogue use
for myomas less than 4 cm. However, Romer does use
them with larger myomas or when they have an impor-
tant intramural component.33 Hallez18 does not use any
hormonal or antihormonal medication pre- or posttreat-
ment. Robert Hart, et al4 do not believe analogue use is
a risk factor for submucous myoma reintervention.
Except in the first years that Danazol was used, we have
used 2 doses of GnRH analogue as preoperative treat-
ment when the myoma was similar in size or bigger than
2 cm, on multiple myoma cases, or when the myomec-
tomy was combined with endometrial resection. No
preparation was used in 32.5 % of our patients because
they were menopausal or because the myoma was small.
However, 60% of our patients received 2 doses of trip-
torelin 3.75 mg before the intervention. Vercellini9 used
this medication in 61.1% of 108 patients.
From the technical point of view, myoma exploration is
very important before beginning the resection. In this
way, the actual myoma size after the analogue effect, as
well as the best way to approach it, is analyzed. We do
not believe it is necessary to use vasoconstricting agents
to avoid excessive bleeding at the cervix as some authors
have recommended.16,34,35 On this issue, we agree with
the majority.36
Antibiotic prophylactic use seems reasonable mainly in
sterile patients, in those with cervicitis, and in long inter-
ventions when the resectoscope goes in and out from the
cavity many times. Many authors14,16,23,26,28,34 support this
idea. The existence sometimes of some serious infectious
complications after surgery reinforces this opinion.4,37
The recommended antibiotics are ampicillin,38 third gen-
eration cephalosporin,12 doxycycline,16 and metronida-
zole.3 In hysteroscopic surgery, we do not use systemat-
ically prophylactic antibiotics. Only in an exceptional
case have we used a dose of a third generation
cephalosporin. Our postoperative infection rate with hys-
teroscopic surgery is very low (0% to 5%), and in our
hysteroscopic myomectomy series, we had 1 case where
the patient had fever 48 hours after the intervention with
a good response to the antibiotics, without actual pelvic
inflammatory disease occurring. We believe thereforeHysteroscopic Myomectomy: Our Experience and Review, Muñoz JL et al.
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that their use is justified only in select cases.
Ultrasonic or laparoscopic intraoperative control becomes
necessary sometimes, mainly with large myomas or in
Wamsteker’s type II.8,16,33,39 However, we do not believe
that is an approach to take routinely.
Fundamental to avoiding complications with glycine,
strict liquid control must be maintained during the inter-
vention, blood pressure must not be allowed to go high-
er than 100 Hg mm (or lower than the patient’s median
arterial pressure), and work must be performed with the
aspiration system open the maximum possible length of
time. Avoiding using the Trendelenburg position and
going in and out many times with the resectoscope will
diminish the rare gas embolism possibilities during these
interventions.16
Regarding the outcome of this intervention, we believe,
as do other authors, that it is a good method for control-
ling AUB. Clinical remission was 80% to 100 % during the
follow-up period of 2 to 7 years.4-11,40-43 Our clinical
improvement rate is 88.5%, which coincides with those
reported in the greatest number of series in the literature
(Table 5). However, the rate declines when the follow-
up period increases. Most of our patients were operated
on during the last third of the decade, and we hope to
see a slow decline in these figures, similar to those
expressed by other authors.5,8,18 However, reintervention
possibilities, such as a hysterectomy or a repeat myomec-
tomy, can be influenced by diverse factors as size and
position of the myomas inside the cavity.5,8,18 Authors
find a greater rate of recurrence with type II myomas.
They also report larger incomplete resection rates. In our
series, we present 22 incomplete resection cases that
increased to 35.2 % (6 cases) with type II myomas. Our
results also coincide with those of other authors with
regards to the 82% of incomplete resection cases occur-
ring when myomas were >3 cm. However, the percent-
age of second myomectomies, 8.4% (9 cases), occurring
in our series corresponds with that of other authors:
5%,11 7.4%,6 19.8%,42 13.1%.5 In only 3 (2.8%) cases did
we resort to a hysterectomy versus the 3.2% reported by
Corson et al35 in 1994 , the 5.8% by Indman in 1993,23
and the 4.9% by Roger Hart in 1999.5 We must empha-
size that of the 22 cases of resection, only 13 were reop-
erated on (9 myomectomies and 3 hysterectomies).
Reintervention was not necessary in the other cases
because of the absence of symptoms or for the apparent
“disappearance” of the remaining myoma. The possibili-
ty of spontaneous regression of the remaining myoma
after an incomplete hysteroscopic myomectomy has
been reported.44
On the other hand, in regards to the repercussions for
fertility, the results are not as satisfactory as they are for
AUB control. Given that submucous myoma as the only
cause of infertility is uncommon,45 it is logical to think
that when no other associated causes exist (masculine
factor, endometriosis, anovulation) the efficacy of hys-
teroscopic myomectomy will be increased.
Fertility after intervention, which was evaluated serious-
Table 5.
AUB Evolution After Hysteroscopic Myomectomy
Author Year No.of Cases Follow-up (years) Control of AUB 
Neuwith4 1976 4 5 100
Derman6 1991 94 9 83.9
Phillips40 1994 150 6 82.1
Parent11 1994 758 5 90
Hallez7 1995 284 5 73.2
Wortman8 1995 75 3 84
Hart5 1999 122 2-3 81.9
Vercellini9 1999 101 3 80
Munoz (this study) 2000 96 1-7* 88.5
*Median period of follow-up: 2.8 years.ly in only a few series, 7,9,10,46-49 was about 31% to 77 %.
Table 6 presents some published gestation figures after
this intervention. Term pregnancy rates ranged from 35%
to 67%. Recently, Bernard, et al49 considered that fertility
after hysteroscopic myomectomy depended on the num-
ber of submucous myomas and the association with
other intramural myomas. Our data are worse: 21.4% of
term pregnancies. 
Other etiological factors associated with sterility-infertili-
ty are the masculine factor, tubal factor, and endometrio-
sis which could partially explain these figures. On the
other hand, we hope to improve these figures as follow-
up time increases.
Although the described complications with these interven-
tions are few, we should not minimize them. Cervical lac-
eration appears frequently.5,15,19 We also had 1 case that
made intervention difficult, and the myoma was not com-
pletely removed. Uterine perforations, during the dilation
or during the intervention, have also been dis-
cussed.5,7,15,35,42,50 We only had 1 case (0.83%) of uterine
perforation in a perimenopausal woman who underwent a
myomectomy plus endometrial resection, the perforation
occurring during the ablation. Laparoscopy was immedi-
ately performed to remove other associated lesions and to
carry out hemostasis. The perforation must be sutured in
patients of reproductive age, even if it is not bleeding,
because of the risk of uterine rupture during pregnancy
and delivery.16,52,53 Another complication that can appear is
hemorrhage, which ranges between 0.5 and 2%.5,8,12,15,54
We had 1 case in our series (0.83 %) resolved by placement
of an intrauterine Foley catheter for 6 hours.
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Numerous published reports exist regarding glycine
extravasation complications with a rate between 0.1%
and 2.5%.5,14,15,42,47,50,54-57 This can be a serious compli-
cation, mainly in older patients or those with heart or
renal disease.16 The entrance and exit controls during the
intervention should be exercised with extreme caution
and the intervention stopped when the balance exceeds
l000 cc. We try to work with pressures lower than 100 Hg
mm and to have the aspiration system open as much as
possible, checking the balance every 15 minutes, stop-
ping the intervention when 1000 to l500 cc is reached. In
this way, our glycine balances are lower than those
reported by other authors. We have not had any serious
cases of glycine extravasation. Only 1 patient whose bal-
ance was l000 cc experienced transitory sickness, nausea,
and time-space disorientation that declined spontaneous-
ly. The lowest sodium value found was 132 mEq/L.
Another possible complication is infection. Numerous
reports14,35,37,52,58,59 exist in the literature about this issue,
even some cases with a fatal outcome.60 In our series, we
had a case which experienced fever 48 hours after sur-
gery and which resolved without problems with intra-
venous antibiotic treatment. We did not have any cases
of electrosurgery injury, nor did we have cervical
stenoses as other authors have reported.15
Histologically, all studies revealed flat muscular fibers;
although in 3 cases an adenomyoma mix component was
noted. Some published cases suggest malignancy (sarco-
ma) after a hysteroscopic myomectomy.7,61,62 Because of
this, we believe it is necessary to send the entire opera-
tive specimen for pathologic examination.
Table 6.
Evolution of Fertility After Hysteroscopic Myomectomy*
Author Year Cases Pregnancy Term Pregnancies
Donnez10 1990 24 16 (67%) 16 (67%)
Brooks 1992 13 10 (77%) 8 (61%)
Gilabert66 1996 69 (55%) (46.2)
Goldenberg47 1995 15 7 (47%) 6 (40%)
Vercellini9 1999 40 16 (40%) 14 (35%)
Bernard49 2000 31 13 (41.9%) 9 (29%)
Muñoz (this study) 2000 14 5 (35.7%) 3 (21.4%)
*Follow-up: 1 to 7 years.Hysteroscopic Myomectomy: Our Experience and Review, Muñoz JL et al.
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A great many authors believe that these techniques pro-
vide lower costs compared with the classic meth-
ods.3,8,16,18,21,36,63-65 Brumsted et al63 in 1996 compared the
hysteroscopic management costs of AUB (ablation/
myomectomy) versus hysterectomy and concluded that
the direct and indirect total costs are significantly lower
with the techniques, even keeping in mind possible rein-
terventions. We also did a study comparing the costs
compared with the supposed management of the 120
patients with that of the classic methods and with the cur-
rent ones. The cost decreased by 39.6%.
CONCLUSION
Hysteroscopic myomectomy is a procedure that is effec-
tive in controlling abnormal uterine bleeding. It is a good
alternative to hysterectomy with an acceptable surgical
time and minimum hospital stay. The bases for reducing
a minimum number of reinterventions are good patient
selection and technique improvement. The technique
also provides important economic savings compared with
the conventional surgical methods.
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